[
  {
    "ts": null,
    "headline": "Tempus Achieves Record Total Contract Value Exceeding $1.1 Billion",
    "summary": "CHICAGO, January 11, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a record Total Contract Value (TCV) of >$1.1 billion as of December 31, 2025. During 2025, Tempus signed data agreements with over 70 customers, spanning both large and mid-sized pharma, including AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Pfizer, Novartis, Merck, Abbvie, Daiichi Sankyo, Eli Lilly, Boehringer Ingelheim, and biotechs inc",
    "url": "https://finnhub.io/api/news?id=75960b0138e2424bbca8b394a2f8ecb84d7afc9c5fc971f2a912f8ee845eacac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768170600,
      "headline": "Tempus Achieves Record Total Contract Value Exceeding $1.1 Billion",
      "id": 138068851,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "CHICAGO, January 11, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a record Total Contract Value (TCV) of >$1.1 billion as of December 31, 2025. During 2025, Tempus signed data agreements with over 70 customers, spanning both large and mid-sized pharma, including AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Pfizer, Novartis, Merck, Abbvie, Daiichi Sankyo, Eli Lilly, Boehringer Ingelheim, and biotechs inc",
      "url": "https://finnhub.io/api/news?id=75960b0138e2424bbca8b394a2f8ecb84d7afc9c5fc971f2a912f8ee845eacac"
    }
  }
]